Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)

Nivolumab met the primary endpoint as second- or third-line treatment for patients with MPM and showed promising efficacy with manageable toxicity.<i>See related commentary by Mansfield and Zauderer, p. 5438</i>.